Drug Trial Radar · NCT06469944
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Sep 20, 2024
Primary completion
Sep 12, 2029
Study completion Sep 12, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for investigational agents in combination with chemotherapy and immunotherapy. There is no formal hypothesis in this study.
Conditions
- Gastroesophageal Junction
- Gastroesophageal Adenocarcinoma
- Esophageal Neoplasms
- Esophageal Cancer
Interventions
PembrolizumabBiological
Administered via intravenous (IV) infusion.
Sacituzumab Tirumotecan (sac-TMT)Biological
Administered via IV infusion.
CapecitabineDrug
Administered via oral tablet.
LeucovorinDrug
Administered via IV infusion.
LevoleucovorinDrug
Administered via IV infusion.
5-Fluorouracil (5-FU)Drug
Administered via IV infusion
OxaliplatinDrug
Administered via IV infusion
Patritumab DeruxtecanBiological
Administered via IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Lead-in Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)Time frame: Up to approximately 28 days
- Safety Lead-in Phase: Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 28 days
- Safety Lead-in Phase: Number of Participants Who Discontinued Study Intervention Due to an AETime frame: Up to approximately 28 days
- Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 28 months
Locations
50 sites in 12 countries. Site status is shown where the registry gives one.
University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927)
Tucson, Arizona · Recruiting
UCLA Hematology/Oncology - Santa Monica ( Site 6905)
Los Angeles, California · Recruiting
Norton Hospital-Norton Cancer Institute - Downtown ( Site 6900)
Louisville, Kentucky · Completed
The Cancer and Hematology Centers ( Site 6912)
Grand Rapids, Michigan · Recruiting
Hematology-Oncology Associates of Central NY, P.C. ( Site 6925)
East Syracuse, New York · Recruiting
Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 6907)
New York, New York · Completed
UPMC Hillman Cancer Center-UPMC ( Site 6904)
Pittsburgh, Pennsylvania · Recruiting
University of Texas MD Anderson Cancer Center ( Site 6920)
Houston, Texas · Recruiting
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 6300)
São Paulo, Brazil · Recruiting
IBCC - Instituto Brasileiro de Controle do Câncer ( Site 6304)
São Paulo, Brazil · Recruiting
Liga Norte Riograndense Contra o Câncer ( Site 6303)
Natal, Rio Grande do Norte, Brazil · Recruiting
Hospital Nossa Senhora da Conceição ( Site 6301)
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Bradford Hill Norte ( Site 6407)
Antofagasta, Chile · Recruiting
Clínica Puerto Montt ( Site 6409)
Port Montt, Los Lagos Region, Chile · Recruiting
Centro de Investigación del Maule ( Site 6408)
Talca, Maule Region, Chile · Completed
FALP-UIDO ( Site 6400)
Santiago, Region M. de Santiago, Chile · Recruiting
Centro de Oncología de Precisión-Oncology ( Site 6404)
Santiago, Region M. de Santiago, Chile · Recruiting
Clínica UC San Carlos de Apoquindo ( Site 6405)
Santiago, Region M. de Santiago, Chile · Recruiting
Bradfordhill-Clinical Area ( Site 6401)
Santiago, Region M. de Santiago, Chile · Recruiting
Beijing Cancer hospital-Digestive Oncology ( Site 5500)
Beijing, Beijing Municipality, China · Recruiting
The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Site 5501)
Fuzhou, Fujian, China · Recruiting
The First Affiliated hospital of Xiamen University ( Site 5503)
Xiamen, Fujian, China · Recruiting
Henan Cancer Hospital ( Site 5504)
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital of Nanchang University ( Site 5514)
Nanchang, Jiangxi, China · Recruiting
Fudan University Shanghai Cancer Center ( Site 5513)
Shanghai, Shanghai Municipality, China · Active not recruiting
Xinjiang Medical University Cancer Hospital - Urumqi ( Site 5506)
Ürümqi, Xinjiang, China · Active not recruiting
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 5510)
Hangzhou, Zhejiang, China · Recruiting
CHU-BREST Cavale Blanche ( Site 5104)
Brest, Finistere, France · Recruiting
Pitie Salpetriere University Hospital-Hepato-Gastro-Enterology ( Site 5102)
Paris, Île-de-France Region, France · Recruiting
CIC. ( Site 5100)
Lille, Nord, France · Recruiting
NCT-Department of Medical Oncology ( Site 6809)
Heidelberg, Baden-Wurttemberg, Germany · Recruiting
HOPE Hamburg/Norddeutsches Studienzentrum fuer Innovative Onkologie ( Site 6807)
Erdgeschoss, Free and Hanseatic City of Hamburg, Germany · Recruiting
Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 6802)
Düsseldorf, North Rhine-Westphalia, Germany · Completed
Ospedale San Raffaele-Oncologia Medica ( Site 5202)
Milan, Italy · Recruiting
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 5207)
Meldola, Emilia-Romagna, Italy · Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 5200)
Milan, Lombardy, Italy · Recruiting
Azienda Ospedaliero Universitaria Pisana ( Site 5206)
Pisa, Tuscany, Italy · Recruiting
Oslo universitetssykehus, Radiumhospitalet ( Site 6501)
Oslo, Norway · Recruiting
Asan Medical Center-Department of Oncology ( Site 5901)
Seoul, South Korea · Recruiting
Samsung Medical Center-Division of Hematology/Oncology ( Site 5900)
Seoul, South Korea · Recruiting
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.